This early study is useful historical evidence, but its treatment grouping makes a simplified thymosin-alpha-1 claim misleading. Primary report
What was reported
Twelve people with chronic hepatitis B entered a prospective placebo-controlled pilot. Seven received thymosin fraction 5 or thymosin-alpha-1, while five received placebo. The report describes favorable viral-DNA and biochemical findings in the combined treated group, with six treated participants versus one placebo participant clearing serum HBV DNA. It reports no significant side effects in this small sample. Primary report
Our appraisal: do not erase material identity
The word “or” in the intervention description matters. A result pooled across two preparations cannot automatically quantify the effect of one of them. Before a compound-specific conclusion is made, the preparation assigned to each participant and the associated outcomes need to be recovered from the full report.
Small denominators also make percentages look more stable than they are. Changing a single participant's outcome can substantially alter a percentage when a group contains only a handful of people. Presenting raw counts alongside percentages helps readers see that sensitivity.
The favorable observation is a reason to examine subsequent controlled evidence, not a basis for presenting a historical pilot as settled clinical practice. Equally, absence of a significant safety signal in a very small trial does not establish absence of uncommon or delayed harms.
This page reviews a historical experiment. It does not identify a commercial research vial as either tested preparation or advise treatment of hepatitis B.
Frequently asked questions
Was only thymosin-alpha-1 tested?
No. The treated group also included thymosin fraction 5.
How large was the study?
Twelve participants overall.
Can the pooled result isolate one preparation?
Not without preparation-specific information.
Why retain the raw counts?
They make the small denominator visible.
Does the pilot establish long-term safety?
No. Its sample cannot resolve uncommon harms.
Is this a current treatment recommendation?
No. It is an appraisal of a historical report.
What source was inspected?
The indexed primary abstract; the complete allocation and methods remain to be checked.